Contenido principal del artículo

Tania Milena Calle Tenesaca
Carlos Enrique Flores Montesinos

La propagación del COVID-19 fue expedita y tras varios informes la eficacia de algunos medicamentos antiinflamatorios no esteroideos, como el ibuprofeno, estuvo bajo sospecha. Mientas que el paracetamol (acetaminofén) se sugirió como una alternativa segura y recomendable para el manejo temprano y domiciliario del dolor y fiebre en pacientes. Objetivo. Comparar el uso del acetaminofén vs ibuprofeno para tratamiento de los síntomas en pacientes con infección por SARS-COV-2”. Metodología. La investigación es una revisión sistemática, donde, se analizaron artículos científicos publicados en revistas vinculadas a áreas de salud, disponibles en buscadores y plataformas digitales tales, como Scienedirect, Pubmed, Elsevier y Springer Link. Las búsquedas se realizaron utilizando las palabras claves previamente definidas. Conclusión. El uso del ibuprofeno ha estado en duda desde sus inicios, en pacientes con COVID-19. Sin embargo, ningún estudio afirma asociar el uso del mismo con aumentos importantes en estadía hospitalaria, ingresos en UCI, necesidad de ventilación mecánica, ni mortalidad. Sin embargo, el acetaminofén ha sido utilizado desde un principio, su uso no estuvo en duda, pero los hallazgos recientes parecen indicar que no es tan eficaz como se pensaba en un principio. Siendo bastante inferior en la comparación directa con el ibuprofeno.

The spread of COVID-19 was expeditious and after several reports the efficacy of some non-steroidal anti-inflammatory drugs, such as ibuprofen, was under suspicion. While paracetamol (acetaminophen) was suggested as a safe and recommended alternative for early and home management of pain and fever in patients. Objective. To compare the use of acetaminophen vs ibuprofen for symptom management in patients with SARS-COV-2 infection". Methodology. The research is a systematic review, where scientific articles published in journals related to health areas, available in search engines and digital platforms such as Scienedirect, Pubmed, Elsevier and Springer Link, were analyzed. Searches were performed using previously defined keywords. Conclusion. The use of ibuprofen has been in question since its inception in patients with COVID-19. However, no study claims to associate its use with significant increases in hospital stay, ICU admissions, need for mechanical ventilation, or mortality. However, acetaminophen has been used from the beginning, its use was not in doubt, but recent findings seem to indicate that it is not as effective as originally thought. It is quite inferior in direct comparison with ibuprofen.

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Cómo citar
Calle Tenesaca, T. M., & Flores Montesinos, C. E. (2023). Comparación: acetaminofén vs ibuprofeno para el tratamiento de los síntomas en pacientes con infección por SARS-CoV-2. Revista Vive, 6(16), 231–239. https://doi.org/10.33996/revistavive.v6i16.221
Sección
ARTÍCULO DE REVISIÓN
Biografía del autor/a

Tania Milena Calle Tenesaca, Universidad Católica de Cuenca. Cuenca, Ecuador

Interno de medicina, Universidad Católica de Cuenca, Ecuador.

Carlos Enrique Flores Montesinos, Universidad Católica de Cuenca. Cuenca, Ecuador

Especialista en Medicina Interna y enfermedades Infecciosas en la Universidad de Chile. Especialista en docencia Universitaria en la Universidad Católica de Cuenca. Experto en ABP, Universidad Católica de Cuenca y Universidad de Leicester Inglaterra. Catedrático de Infectología carrera de medicina Universidad Católica de Cuenca. Coordinador de Investigación formativa Carrera de Medicina, Universidad Católica de Cuenca. Médico tratante del Hospital Latinoamericano, Ecuador.

Referencias

Carlotti AP, Carvalho WB, Johnston C, Rodríguez IS, Delgado AF. Diagnostic and Management Protocol for pediatric patients. Clinics. 2020; 75 (Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153362/

Moore N, Bosco-Levy P, Thurin N, Blin P, Droz-Perroteau C. NSAIDs and COVID-19: A Systematic Review and Meta-analysis. Drug Saf. 2021;44(9):929-38. p. 270-3. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34339037/

Pathak EB, Salemi JL, Sobers N, Menard J, Hambleton IR. COVID-19 in Children in the United States: Intensive Care Admissions, Estimated Total Infected, and Projected Numbers of Severe Pediatric Cases in 2020. J Public Health Manag Pract. 20 de abril de 2020;10.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395. p. 497-506. Disponible en: https://www.thelancet.com/article/S0140-6736(20)30183-5/fulltext

Kutti Sridharan G, Kotagiri R, Chandiramani VH, Mohan BP, Vegunta R, Vegunta R, et al. COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence? Am J Ther. 27 de abril de 2020;10.1097/MJT.0000000000001196.

Pergolizzi JV, Varrassi G, Magnusson P, LeQuang JA, Paladini A, Taylor R, et al. COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns. Pain Ther. diciembre de 2020;9(2):353-8.

Zhu F, Ang JY. COVID-19 Infection in Children: Diagnosis and Management. Curr Infect Dis Report. 2022; 24(Disponible en: https://doi.org/10.1007/s11908-022-00779-0): p. 51-62.

Jamerson BD, Haryadi TH. The use of ibuprofen to treat fever in COVID-19: A possible indirect association with worse outcome? Med Hypotheses. noviembre de 2020;144:109880.

Kauffman RE, Sawyer LA, Scheinbaum ML. Antipyretic efficacy of ibuprofen vs acetaminophen. Am J Dis Child. mayo de 2012;146(5):622-5. doi:10.1001/archpedi.1992.02160170102024

Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. junio de 2015;15(6):335-49. https://www.nature.com/articles/nri3843

Rinott E, Kozer E, Shapira Y, et al. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020; 26(9) Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289730/.

Kushner P, McCarberg BH, Grange L, et al. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19. Primary Care Respiratory Medicine. 2022; 32(35) Disponible en: https://www.nature.com/articles/s41533-022-00300-z.

Abu LC, Algahtani RA, Thomas A, et al. Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study. Infectious Diseases and Therapy. 2021; 10(253-268) Disponible en: https://link.springer.com/article/10.1007/s40121-020-00363-w.

Manjani L, Desai N, Kholi A, et al. Effects of acetaminiophen on outcomes in patients hospitalised with covid 19. Chest. 2021; 160(4) Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503320/

Campbell HM, Murata AE, Conner TA. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality among United States Veterans after testing positive for COVID-19. PLoS ONE. 2022; 17(5) Disponibel en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267462.

Drake, T M, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lanc. Rheum. 2021; 3 (e498–506) Disponbile en: https://www.thelancet.com/action/showPdf?pii=S2665-9913%2821%2900104-1

Zhou Q, et al. Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: A systematic review and meta-analysis. Lancet. 2022; 46. Disponible en: https://www.sciencedirect.com/science/article/pii/S2589537022001031.

Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19(141-154) Disponible en: https://www.nature.com/articles/s41579-020-00459-7): p. 141-54

Klucka J, Klabusayova E, Kratochvil M, Musilova T, Vafek V, Skrisovska T. Critically Ill Pediatric Patient and SARS-CoV-2 Infection. Children. 2022; 9 .Disponible en: https://doi.org/10.3390/children9040538.

Santos N, Yu Y, Chen Y, et al. Paracetamol Is Associated with a Lower Risk of COVID-19 Infection and Decreased ACE2 Protein Expression: A Retrospective Analysis. Covid. 2021; 1(1) Disponible en: https://www.mdpi.com/2673-8112/1/1/18.

Lapi F, Marconi E, Grattagliano I, et al. To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case–control analysis, in primary care. Intern Emerg Med. 2022; 30(Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362076/.

Abdelgany TM, Ganash M, Bakri MM, Qanash H, Al-Rajhi AM, Elhussieny NI. SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions. Biomed J. 2021; 44. Disponible en:https://reader.elsevier.com/reader/sd/pii/S2319417020301797?token=E3DA2C7FCC814870EED542ED66BE315FA1289C24089022BEF8AC01F660DB05A2BF282604903D89F6694843E50F1C4684

Reese JT, Coleman B, Chan L, et al. NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study. Vir. Journ. 2022; 19(84) Disponible en: https://virologyj.biomedcentral.com/articles/10.1186/s12985-022-01813-2.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020; p. 934-43. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32167524/